We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN) Reports Q4 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
Illumina (ILMN - Free Report) reported $1.12 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 3.6%. EPS of $0.14 for the same period compares to $0.14 a year ago.
The reported revenue represents a surprise of +3.11% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $0.01, the EPS surprise was +1300.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Illumina performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- GRAIL: $30 million versus $26.26 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +30.4% change.
Revenue- Microarrays- Instruments: $6 million compared to the $4.63 million average estimate based on four analysts. The reported number represents a change of +20% year over year.
Revenue- Service and other revenue: $199 million versus the four-analyst average estimate of $187.72 million. The reported number represents a year-over-year change of +17.1%.
Revenue- Microarrays- Consumables: $74 million compared to the $76.71 million average estimate based on four analysts. The reported number represents a change of -7.5% year over year.
Revenue- Product revenue: $923 million compared to the $889.86 million average estimate based on four analysts. The reported number represents a change of +1.1% year over year.
Revenue- Sequencing- Instruments: $161 million compared to the $142.78 million average estimate based on four analysts. The reported number represents a change of +10.3% year over year.
Revenue- Sequencing- Consumables: $687 million versus the four-analyst average estimate of $665.74 million. The reported number represents a year-over-year change of 0%.
Revenue- Microarrays- Total: $97 million versus the three-analyst average estimate of $103.76 million. The reported number represents a year-over-year change of -4%.
Revenue- Sequencing- Total: $1 billion compared to the $955.79 million average estimate based on three analysts. The reported number represents a change of +3.7% year over year.
Revenue- Core Illumina: $1.10 billion compared to the $1.05 billion average estimate based on three analysts. The reported number represents a change of +3% year over year.
Revenue- Sequencing- Service & Other: $152 million compared to the $181.18 million average estimate based on three analysts. The reported number represents a change of +16% year over year.
Revenue- Microarrays- Service & Other: $17 million versus $19.62 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.
Shares of Illumina have returned +1.6% over the past month versus the Zacks S&P 500 composite's +6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Illumina (ILMN) Reports Q4 Earnings: What Key Metrics Have to Say
Illumina (ILMN - Free Report) reported $1.12 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 3.6%. EPS of $0.14 for the same period compares to $0.14 a year ago.
The reported revenue represents a surprise of +3.11% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $0.01, the EPS surprise was +1300.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Illumina performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- GRAIL: $30 million versus $26.26 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +30.4% change.
- Revenue- Microarrays- Instruments: $6 million compared to the $4.63 million average estimate based on four analysts. The reported number represents a change of +20% year over year.
- Revenue- Service and other revenue: $199 million versus the four-analyst average estimate of $187.72 million. The reported number represents a year-over-year change of +17.1%.
- Revenue- Microarrays- Consumables: $74 million compared to the $76.71 million average estimate based on four analysts. The reported number represents a change of -7.5% year over year.
- Revenue- Product revenue: $923 million compared to the $889.86 million average estimate based on four analysts. The reported number represents a change of +1.1% year over year.
- Revenue- Sequencing- Instruments: $161 million compared to the $142.78 million average estimate based on four analysts. The reported number represents a change of +10.3% year over year.
- Revenue- Sequencing- Consumables: $687 million versus the four-analyst average estimate of $665.74 million. The reported number represents a year-over-year change of 0%.
- Revenue- Microarrays- Total: $97 million versus the three-analyst average estimate of $103.76 million. The reported number represents a year-over-year change of -4%.
- Revenue- Sequencing- Total: $1 billion compared to the $955.79 million average estimate based on three analysts. The reported number represents a change of +3.7% year over year.
- Revenue- Core Illumina: $1.10 billion compared to the $1.05 billion average estimate based on three analysts. The reported number represents a change of +3% year over year.
- Revenue- Sequencing- Service & Other: $152 million compared to the $181.18 million average estimate based on three analysts. The reported number represents a change of +16% year over year.
- Revenue- Microarrays- Service & Other: $17 million versus $19.62 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.
View all Key Company Metrics for Illumina here>>>Shares of Illumina have returned +1.6% over the past month versus the Zacks S&P 500 composite's +6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.